Mr. John Hennessy:

The switch to biosimilars is a high priority in the Department and HSE. The agreement in place between the State and the pharmaceutical industry provides for value on the launch of the biosimilar. Regardless of what is prescribed after the launch of the biosimilar, we get the discount.